McDermott Advises TreeFrog Therapeutics on its Collaboration with Umoja Biopharma
McDermott Will & Emery has advised TreeFrog Therapeutics, a French-based biotech company aiming to unlock access to cell therapies for millions of patients, on its collaboration with Umoja Biopharma, Inc. to evaluate Umoja’s iPSC platform within TreeFrog’s C-Stem™ technology for scalable expansion and immune cell differentiation in bioreactors for the mass-production of stem-cell derived therapies addressing hematologic and solid tumors.
The McDermott team that advised TreeFrog Therapeutics comprised:
Emmanuelle Trombe, partner, and Edouard Becker, associate.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.